Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.

por Keller J Toral, Mark A Wuenschel, Esther P Black
Publicado 2021

A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC

por Madeline Krentz Gober, James P. Collard, Katherine Thompson, Esther P. Black
Publicado 2017